ⓘ SB-269970

                                     

ⓘ SB-269970

SB-269970 is a drug and research chemical developed by GlaxoSmithKline used in scientific studies. It is believed to act as a selective 5-HT 7 receptor antagonist. A subsequent study in guinea pig at 10 uM showed that it also blocks the α 2 -adrenergic receptor activity. The significant difference in test concentrations, however, confirms the selectivity of SB-269970 for the 5-HT 7 receptor.

SB-269970 is used to study 5-HT 7 receptors, which are believed to be involved in the functioning of certain areas of the brain such as the hippocampus and the thalamus, as well as the regulation of dopamine release in the ventral region of tyre. Possible therapeutic uses for SB-269970 and other 5-HT 7 antagonists include the treatment of anxiety and depression, and nootropic effects were noted in animal studies.